Research
Metabolic adaptation
Initiation of protease inhibitor (PI) therapy in HIV-infected patients leads to significant increases in glucose (+9+/-3 mg/dl; p = .0136), insulin (+12.2+/-4.9 U/ml; p = .023), triglycerides (+53+/-17 mg/dl; p = .0069), and total and LDL cholesterol (+32+/-11 and +18+/-5 mg/dl; p = .0082 and .0026, respectively).
Healthcare providers should monitor glucose and lipid levels in HIV patients starting PI therapy due to potential metabolic changes.
StrongSupportsmedium confidence
Nonetheless, in patients beginning PI therapy, there were significant increases in glucose (+9+/-3 mg/dl; p = .0136), insulin (+12.2+/-4.9 U/ml; p = .023), triglycerides (+53+/-17 mg/dl; p = .0069), and total and LDL cholesterol (+32+/-11 and +18+/-5 mg/dl; p = .0082 and .0026, respectively).
Why this rating
The study design involves paired data analysis in a clinical context.
Source
Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection
Kathleen Mulligan et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2000
cohort · n=41Cited 499×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →